{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:30:53Z","timestamp":1781346653848,"version":"3.54.1"},"reference-count":103,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.nephro.2016.12.002","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T18:00:23Z","timestamp":1484589623000},"page":"43-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u00c9changes plasmatiques en n\u00e9phrologie\u00a0: techniques et indications"],"prefix":"10.1684","volume":"13","author":[{"given":"Christophe","family":"Ridel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mesnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Hertig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2016.12.002_bib0520","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1053\/j.ajkd.2008.02.360","article-title":"Therapeutic plasma exchange: core curriculum 2008","volume":"52","author":"Kaplan","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.12.002_bib0525","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1526-0968.2000.00201.x","article-title":"Apheresis registry in France: indications, techniques, and complications","volume":"4","author":"Korach","year":"2000","journal-title":"Ther Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0530","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/039139888400700106","article-title":"A comparison of centrifugal and membrane-based apheresis formats","volume":"7","author":"Gurland","year":"1984","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2016.12.002_bib0535","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000183148","article-title":"Comparative evaluation of filters used in membrane plasmapheresis","volume":"36","author":"Gurland","year":"1984","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2016.12.002_bib0540","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/(SICI)1098-1101(1997)12:3<146::AID-JCA8>3.0.CO;2-A","article-title":"Alternatives to albumin: starch replacement for plasma exchange","volume":"12","author":"Brecher","year":"1997","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0545","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s001340050595","article-title":"Role of replacement fluids in the immediate complications of plasma exchange","volume":"24","author":"Korach","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0550","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00540-010-1034-y","article-title":"Colloid solutions: a clinical update","volume":"24","author":"Niemi","year":"2010","journal-title":"J Anesth"},{"key":"10.1016\/j.nephro.2016.12.002_bib0555","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0750-7658(94)80038-3","article-title":"R\u00e9actions anaphylacto\u00efdes aux substituts collo\u00efdaux du plasma\u00a0: incidence, facteurs de risque, m\u00e9canismes. Enqu\u00eate prospective multicentrique fran\u00e7aise","volume":"13","author":"Laxenaire","year":"1994","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.nephro.2016.12.002_bib0560","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1055\/s-0038-1657671","article-title":"Coagulation disorders caused by hydroxyethyl starch","volume":"78","author":"Treib","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.nephro.2016.12.002_bib0565","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJM200108233450818","article-title":"Acquired type\u00a0I von Willebrand's disease associated with highly substituted hydroxyethyl starch","volume":"345","author":"Jonville-B\u00e9ra","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0570","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0140-6736(93)92345-T","article-title":"Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation","volume":"342","author":"Legendre","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2016.12.002_bib0575","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/bja\/aem068","article-title":"HES 130\/0.42\u00a0shows less alteration of pharmacokinetics than HES 200\/0.5\u00a0when dosed repeatedly","volume":"98","author":"Lehmann","year":"2007","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.nephro.2016.12.002_bib0580","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1213\/ane.0b013e31817e6eac","article-title":"The effects of hydroxyethyl starch 130\/0.4 (6\u00a0%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials","volume":"107","author":"Kozek-Langenecker","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1016\/j.nephro.2016.12.002_bib0585","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/bja\/aen001","article-title":"Comparison of the novel hydroxyethylstarch 130\/0.4\u00a0and hydroxyethylstarch 200\/0.6\u00a0in brain-dead donor resuscitation on renal function after transplantation","volume":"100","author":"Blasco","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.nephro.2016.12.002_bib0590","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s001340051211","article-title":"Determination of the clearance factor for transmissible spongiform encephalopathy agents during the manufacturing process of polygeline","volume":"26","author":"Peano","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0595","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/bja\/aep393","article-title":"Use of albumin: an update","volume":"104","author":"Boldt","year":"2010","journal-title":"Br J Anaesth"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.nephro.2016.12.002_bib0600","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1097\/01.CCM.0000214293.72918.D8","article-title":"Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies","volume":"34","author":"Curtis","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0605","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jca.10013","article-title":"Transfusion-related acute lung injury during plasma exchange: suspecting the unsuspected","volume":"17","author":"Askari","year":"2002","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0610","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.transci.2010.09.004","article-title":"Haemovigilance: are there significant differences among plasma products?","volume":"43","author":"Mayr","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.nephro.2016.12.002_bib0615","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"Del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0620","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1096\/fj.11-180752","article-title":"Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis","volume":"25","author":"Mesnard","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.nephro.2016.12.002_bib0625","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","article-title":"Complications of therapeutic plasma exchange: experience with 4857\u00a0treatments","volume":"9","author":"Basic-Jukic","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nephro.2016.12.002_bib0630","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.mnh.0000247503.87162.15","article-title":"Plasmapheresis in nephrology: an update","volume":"15","author":"Rahman","year":"2006","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nephro.2016.12.002_bib0635","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jca.20240","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis","volume":"25","author":"Szczepiorkowski","year":"2010","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0640","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American college of chest physicians task force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.nephro.2016.12.002_bib0645","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jca.20134","article-title":"The new approach to assignment of ASFA categories \u2013 introduction to the fourth special issue: clinical applications of therapeutic apheresis","volume":"22","author":"Szczepiorkowski","year":"2007","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0650","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(01)06077-9","article-title":"Goodpasture's disease","volume":"358","author":"Salama","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2016.12.002_bib0655","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson","year":"1985","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2016.12.002_bib0660","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/md.0b013e318067da56","article-title":"Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28\u00a0cases","volume":"86","author":"Lazor","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2016.12.002_bib0665","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2016.12.002_bib0670","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1681\/ASN.2011030298","article-title":"Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles","volume":"23","author":"Hong","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0675","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0680","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1681\/ASN.2007010066","article-title":"EUVAS. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis","volume":"18","author":"De Lind van Wijngaarden","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0685","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for induction and cyclosporine\u00a0A for maintenance of remission in Wegener's granulomatosis \u2013 a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib0690","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.12.002_bib0695","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis","volume":"326","author":"Lewis","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0700","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(83)91561-1","article-title":"Randomised trial of plasma exchange in mild systemic lupus erythematosus","volume":"1","author":"Wei","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2016.12.002_bib0705","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/jaut.1998.0229","article-title":"Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus","volume":"11","author":"Gaubitz","year":"1998","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nephro.2016.12.002_bib0710","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1526-0968.2002.00400.x","article-title":"Apheresis in cryoglobulinemia complicating hepatitis\u00a0C and in other renal diseases","volume":"6","author":"Dominguez","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0715","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis\u00a0C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nephro.2016.12.002_bib0720","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1537-2995.1980.20280169957.x","article-title":"Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia","volume":"20","author":"Berkman","year":"1980","journal-title":"Transfusion"},{"key":"10.1016\/j.nephro.2016.12.002_bib0725","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1526-0968.2001.00357.x","article-title":"Current topics on cryofiltration technologies","volume":"5","author":"Siami","year":"2001","journal-title":"Ther Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0730","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jca.20222","article-title":"Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia","volume":"24","author":"Stefanutti","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0735","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1526-0968.2003.00036.x","article-title":"Indications of plasma exchanges for systemic vasculitides","volume":"7","author":"Guillevin","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nephro.2016.12.002_bib0740","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2169\/naika.77.494","article-title":"Combined treatment of plasmapheresis and methylprednisolone pulse therapy to polyarteritis nodosa with rapidly progressive glomerulonephritis","volume":"77","author":"Terada","year":"1988","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"10.1016\/j.nephro.2016.12.002_bib0745","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-0502(01)00078-7","article-title":"Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity","volume":"25","author":"Cozzi","year":"2001","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.nephro.2016.12.002_bib0750","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jca.2920010404","article-title":"Plasma exchange: a controlled study of the effect in patients with Raynaud's phenomenon and scleroderma","volume":"1","author":"McCune","year":"1983","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0755","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","article-title":"Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12\u00a0months: follow-up of immunopathological and clinical effects","volume":"28","author":"Szekanecz","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0760","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.clim.2011.09.014","article-title":"Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis","volume":"142","author":"Papp","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0765","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50\u00a0patients","volume":"77","author":"Asherson","year":"1998","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2016.12.002_bib0770","first-page":"508","article-title":"The catastrophic antiphospholipid syndrome","volume":"19","author":"Asherson","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0775","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.autrev.2008.09.002","article-title":"Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature","volume":"8","author":"Bortolati","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nephro.2016.12.002_bib0780","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1098-1101(1999)14:4<171::AID-JCA3>3.0.CO;2-5","article-title":"Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein\u00a0I antibodies as a marker of response to therapy","volume":"14","author":"Flamholz","year":"1999","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib0785","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.transci.2004.10.025","article-title":"The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome","volume":"33","author":"Uthman","year":"2005","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.nephro.2016.12.002_bib0790","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0795","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"82","author":"Coppo","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2016.12.002_bib0800","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials","volume":"53","author":"Michael","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.12.002_bib0805","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1056\/NEJM199508103330608","article-title":"Escherichia coli O157:H7\u00a0and the hemolytic-uremic syndrome","volume":"333","author":"Boyce","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.nephro.2016.12.002_bib0810","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/ki.2008.624","article-title":"Treatment options for HUS secondary to Escherichia coli O157:H7","volume":"112","author":"Bitzan","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.12.002_bib0815","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(99)01251-9","article-title":"Effectiveness of therapeutic plasma exchange in the 1996\u00a0Lanarkshire Escherichia coli O157:H7\u00a0outbreak","volume":"354","author":"Dundas","year":"1999","journal-title":"Lancet"},{"issue":"Suppl.","key":"10.1016\/j.nephro.2016.12.002_bib0820","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.615","article-title":"Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis","volume":"112","author":"Tarr","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.12.002_bib0825","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0830","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0835","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor\u00a0H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3\u00a0in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2016.12.002_bib0840","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1399-3046.2010.01345.x","article-title":"Actual and future strategies for transplantation in atypical HUS associated with mutations in factor\u00a0H","volume":"15","author":"Riedl","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib0845","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0850","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0855","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/TP.0b013e31820f08e8","article-title":"The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction","volume":"91","author":"Uchida","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0860","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/01.tp.0000262570.18117.55","article-title":"Implementation of a protocol for ABO-incompatible kidney transplantation \u2013 a three-center experience with 60\u00a0consecutive transplantations","volume":"83","author":"Tyd\u00e9n","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0865","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2215\/CJN.02940311","article-title":"Incompatible live-donor kidney transplantation in the United States: results of a national survey","volume":"6","author":"Garonzik Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0870","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1537-2995.2008.02085.x","article-title":"Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation","volume":"49","author":"Tobian","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.nephro.2016.12.002_bib0875","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/TP.0b013e31823360cf","article-title":"Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic?","volume":"92","author":"Lawrence","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0880","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfr610","article-title":"Anti-A\/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption","volume":"27","author":"Wahrmann","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib0885","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/TP.0b013e31821c93bb","article-title":"Luminex-based desensitization protocols: the University of Wisconsin initial experience","volume":"92","author":"Niederhaus","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0890","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/TP.0b013e3181d21e7f","article-title":"Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation","volume":"89","author":"Vo","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0895","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/TP.0b013e3181919a16","article-title":"Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience","volume":"87","author":"Thielke","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0900","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0905","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/ndt\/17.8.1503","article-title":"Perioperative immunoadsorption in sensitized renal transplant recipients","volume":"17","author":"Haas","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib0910","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5301\/jn.5000048","article-title":"The mechanisms of acute transplant rejection revisited","volume":"25","author":"Ponticelli","year":"2012","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0915","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/TP.0b013e3181da1cc3","article-title":"Combined posttransplant prophylactic IVIg\/anti-CD 20\/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study","volume":"89","author":"Loupy","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0920","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination plasmapheresis\/IVIg\/anti-CD20\u00a0versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib0925","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2215\/CJN.05321107","article-title":"Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies","volume":"3","author":"Akalin","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0930","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein\u00a0C5\u00a0for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib0935","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/TP.0b013e31819f12be","article-title":"Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence","volume":"87","author":"Hickson","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2016.12.002_bib0940","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM199604043341402","article-title":"Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis","volume":"334","author":"Savin","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0945","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0950","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1525-1594.2010.01068.x","article-title":"Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation","volume":"35","author":"Tsagalis","year":"2011","journal-title":"Artif Organs"},{"key":"10.1016\/j.nephro.2016.12.002_bib0955","first-page":"928","article-title":"LDL-apheresis for refractory nephrotic syndrome","volume":"52","author":"Muso","year":"2010","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.nephro.2016.12.002_bib0960","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1542-4758.2010.00481.x","article-title":"Role of plasmapheresis in the management of myeloma kidney: a systematic review","volume":"14","author":"Gupta","year":"2010","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nephro.2016.12.002_bib0965","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/ki.1988.127","article-title":"Controlled plasma exchange trial in acute renal failure due to multiple myeloma","volume":"33","author":"Zucchelli","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.12.002_bib0970","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0975","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib0980","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1182\/blood-2010-04-279869","article-title":"Hyperviscosity syndrome","volume":"117","author":"Sigle","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2016.12.002_bib0985","first-page":"69","article-title":"Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstr\u00f6m and multiple myeloma: influence on blood rheology and the microcirculation","volume":"119","author":"Reinhart","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0990","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-58-5-789","article-title":"Plasmapheresis therapy in macroglobulinemia","volume":"58","author":"Solomon","year":"1963","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2016.12.002_bib0995","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/039139880803101009","article-title":"Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis","volume":"31","author":"Tsagalis","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2016.12.002_bib1000","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jca.20170","article-title":"Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis: three case reports and review of literature","volume":"23","author":"Mathur","year":"2008","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2016.12.002_bib1005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000418554","article-title":"Available removal systems: state of the art","volume":"57","author":"Sawada","year":"1990","journal-title":"Curr Stud Hematol Blood Transfus"},{"key":"10.1016\/j.nephro.2016.12.002_bib1010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/039139888600900519","article-title":"Selective removal of pathogenetic macromolecules directly from whole blood by double filtration technique","volume":"9","author":"Agishi","year":"1986","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nephro.2016.12.002_bib1015","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/ndt\/gfq264","article-title":"Immunoadsorption in nephrology and kidney transplantation","volume":"25","author":"Schwenger","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.12.002_bib1020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1526-0968.2003.00070.x","article-title":"Low-density lipoprotein apheresis: an overview","volume":"7","author":"Bambauer","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nephro.2016.12.002_bib1025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1681\/ASN.V91121","article-title":"Successful treatment of recurrent rejection in renal transplant patients with photopheresis","volume":"9","author":"Dall\u2019Amico","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.12.002_bib1030","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.tp.0000261635.30578.d8","article-title":"Induction of regulatory T\u00a0cells after prophylactic treatment with photopheresis in renal transplant recipients","volume":"83","author":"Lamioni","year":"2007","journal-title":"Transplantation"}],"container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725516306459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725516306459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2016.12.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:37:56Z","timestamp":1741192676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725516306459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1769725516306459"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2016.12.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9changes plasmatiques en n\u00e9phrologie\u00a0: techniques et indications","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS on behalf of Association Soci\u00e9t\u00e9 de n\u00e9phrologie.","name":"copyright","label":"Copyright"}]}}